Literature DB >> 16092584

Medication-induced hyperprolactinemia.

Mark E Molitch1.   

Abstract

Medication use is a common cause of hyperprolactinemia, and it is important to differentiate this cause from pathologic causes, such as prolactinomas. To ascertain the frequency of this clinical problem and to develop treatment guidelines, the medical literature was searched by using PubMed and the reference lists of other articles dealing with hyperprolactinemia due to specific types of medications. The medications that most commonly cause hyperprolactinemia are antipsychotic agents; however, some newer atypical antipsychotics do not cause this condition. Other classes of medications that cause hyperprolactinemia include antidepressants, antihypertensive agents, and drugs that increase bowel motility. Hyperprolactinemia caused by medications is commonly symptomatic, causing galactorrhea, menstrual disturbance, and impotence. It is Important to ensure that hyperprolactinemia in an Individual patient is due to medication and not to a structural lesion in the hypothalamic/pituitary area; this can be accomplished by (1) stopping the medication temporarily to determine whether prolactin levels return to normal, (2) switching to a medication that does not cause hyperprolactinemia (in consultation with the patient's psychiatrist for psychoactive medications), or (3) performing magnetic resonance imaging or computed tomography of the hypothalamic/pituitary area. If the patient's hyperprolactinemia is symptomatic, treatment strategies include switching to an alternative medication that does not cause hyperprolactinemia, using estrogen or testosterone replacement, or, rarely, cautiously adding a dopamine agonist.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16092584     DOI: 10.4065/80.8.1050

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  42 in total

1.  Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level.

Authors:  Marc De Hert; Dan Cohen; Julio Bobes; Marcelo Cetkovich-Bakmas; Stefan Leucht; David M Ndetei; John W Newcomer; Richard Uwakwe; Itsuo Asai; Hans-Jurgen Möller; Shiv Gautam; Johan Detraux; Christoph U Correll
Journal:  World Psychiatry       Date:  2011-06       Impact factor: 49.548

2.  Serotonin reuptake inhibitors and hyperprolactinaemia: a case/non-case study in the French pharmacovigilance database.

Authors:  Thierry Trenque; Emmanuelle Herlem; Pascal Auriche; Moustapha Dramé
Journal:  Drug Saf       Date:  2011-12-01       Impact factor: 5.606

3.  The possible role of fluoxetine in adenomyosis: an animal experiment with clinical correlations.

Authors:  Parama Sengupta; Abhishek Sharma; Gautameswar Mazumdar; Indranil Banerjee; Santanu K Tripathi; Chiranjib Bagchi; Nina Das
Journal:  J Clin Diagn Res       Date:  2013-07-01

4.  Increase in clusterin-containing follicles in the adenohypophysis of drug abusers.

Authors:  Takaki Ishikawa; Bao-Li Zhu; Satoru Miyaishi; Hideo Ishizu; Hitoshi Maeda
Journal:  Int J Legal Med       Date:  2006-11-18       Impact factor: 2.686

5.  Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy.

Authors:  Giovan B Cassano; Andrea Fagiolini; Lorenzo Lattanzi; Palmiero Monteleone; Cinzia Niolu; Emilio Sacchetti; Alberto Siracusano; Antonio Vita
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

6.  Clinical Course of Nonfunctional Pituitary Microadenoma in Children: A Single-Center Experience.

Authors:  Vidhu V Thaker; Adrianne E Lage; Garima Kumari; V Michelle Silvera; Laurie E Cohen
Journal:  J Clin Endocrinol Metab       Date:  2019-12-01       Impact factor: 5.958

7.  Adenomyosis: Epidemiology, Risk Factors, Clinical Phenotype and Surgical and Interventional Alternatives to Hysterectomy.

Authors:  F A Taran; E A Stewart; S Brucker
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-09       Impact factor: 2.915

8.  Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients.

Authors:  L Vilar; M C Freitas; L A Naves; L A Casulari; M Azevedo; R Montenegro; A I Barros; M Faria; G C Nascimento; J G Lima; L H Nóbrega; T P Cruz; A Mota; A Ramos; A Violante; A Lamounier Filho; M R Gadelha; M A Czepielewski; A Glezer; M D Bronstein
Journal:  J Endocrinol Invest       Date:  2008-05       Impact factor: 4.256

Review 9.  Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review.

Authors:  Chaya G Bhuvaneswar; Ross J Baldessarini; Veronica L Harsh; Jonathan E Alpert
Journal:  CNS Drugs       Date:  2009-12       Impact factor: 5.749

10.  Estrogen and comprehension of metaphoric speech in women suffering from schizophrenia: results of a double-blind, placebo-controlled trial.

Authors:  Niels Bergemann; Peter Parzer; Susanne Jaggy; Beatrice Auler; Christoph Mundt; Sabine Maier-Braunleder
Journal:  Schizophr Bull       Date:  2007-12-21       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.